Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Actavis Realigns Business To Increase Efficiency

This article was originally published in The Pink Sheet Daily

Executive Summary

The global specialty brand and generics company is simplifying its structure and combining units to make communication and decisions across the business more effective as it strives to grow organically.

You may also be interested in...

Actavis Divests In China But Looking For Acquisition; CEO Says Pfizer’s Established Products Division Possible

Actavis is pulling out of China because its business there is too small and complicated considering the investment of time and capital that could be better spent elsewhere But it could re-enter via a sizeable acquisition, such as Pfizer’s Established Products division.

Watson Begins Anew As Actavis, Focuses On Organic Growth

The traditionally generic-heavy company now has an expanded global presence and a growing branded business to go with its new name.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts